NKAIN3: A Potential Drug Target and Biomarker (G286183)

Target Name: NKAIN3

NCBI ID: G286183

NKAIN3

NKAIN3: A Potential Drug Target and Biomarker

Introduction

NKAIN3, or N-acyl-KEToglutarate-Inositol-Nadphinic Acid-Creatinyl-Lycyl-Glu (N-acyl-KEToglutarate-Inositol-Nadphinic Acid-Creatinyl-Lycyl-Glu), is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. NKAIN3 is a key regulator of the insulin sensitivity and inflammation pathways, and its dysfunction has been implicated in numerous diseases, including type 2 diabetes, obesity, and cardiovascular disease.

The NKAIN3 molecule

NKAIN3 is a 21-kDa protein that is expressed in various tissues, including liver, pancreas, and muscle. It is composed of a unique transmembrane domain, a cytoplasmic domain, and an amino-terminal domain that is involved in protein-protein interactions and modulation of cellular signaling pathways. NKAIN3 has been shown to play a role in multiple cellular processes, including metabolism, inflammation, and signaling pathways.

NKAIN3 and diabetes

NKAIN3 has been shown to be involved in the regulation of insulin sensitivity and glucose metabolism. NKAIN3 has been shown to enhance the sensitivity of muscle and liver tissues to insulin, indicating that it may have a potential role in the treatment of type 2 diabetes. Additionally , NKAIN3 has been shown to regulate the expression of genes involved in insulin sensitivity and glucose metabolism, suggesting that it may have a potential role in the treatment of obesity and other metabolic disorders.

NKAIN3 and obesity

NKAIN3 has also been shown to be involved in the regulation of obesity and metabolism. NKAIN3 has been shown to increase the expression of genes involved in energy metabolism and to reduce the expression of genes involved in lipid metabolism. These effects may contribute to the development and maintenance of obesity. Additionally, NKAIN3 has been shown to increase the expression of genes involved in inflammation and cellular signaling, which may contribute to the development of metabolic disorders, including obesity.

NKAIN3 and cardiovascular disease

NKAIN3 has also been shown to be involved in the regulation of cardiovascular disease. Additionally, NKAIN3 has been shown to increase the expression of genes involved in inflammation and cellular signaling, which may contribute to the development and progression of cardiovascular disease. to enhance the sensitivity of blood vessels to insulin, indicating that it may have a potential role in the treatment of cardiovascular disease.

NKAIN3 as a drug target or biomarker

NKAIN3 has important clinical prospects as a drug target or biomarker. By targeting the regulatory effects of NKAIN3, drugs can be developed to treat diabetes, obesity, and cardiovascular disease. In addition, NKAIN3 can also be used as a biomarker to study cell signaling and metabolic regulation mechanisms, providing important experimental basis for studying these mechanisms.

in conclusion

In summary, NKAIN3 is a drug target and biomarker with great potential. By regulating the activity of NKAIN3, diabetes, obesity and cardiovascular diseases can be treated, bringing new hope for clinical treatment.

Protein Name: Sodium/potassium Transporting ATPase Interacting 3

The "NKAIN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NKAIN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets